Overview
US biopharmaceutical firm posts full-year collaboration revenue, beating analyst expectations
Net loss for 2025 widened as R&D and G&A expenses increased
Company completed $132.3 mln upsized follow-on public offering to fund operations through 2029
Outlook
Company expects existing cash to fund operations through 2029
Result Drivers
COLLABORATION REVENUE - First-time collaboration revenue driven by Novartis research agreement initiated in 2025
HIGHER R&D SPENDING - Increased R&D expenses due to expanded activities for BGE-102, Novartis collaboration, and APJ agonist programs
INCREASED G&A EXPENSES - Higher G&A costs mainly from increased personnel expenses, legal fees, and insurance
Company press release: ID:nGNX9GGXd4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Collaboration Revenue | Beat | $9 mln | $7.11 mln (7 Analysts) |
FY EPS | -$2.24 | ||
FY Net Income | -$80.61 mln | ||
FY Income from Operations | -$92.78 mln | ||
FY Operating Expenses | $101.78 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BIOAGE Labs Inc is $52.00, about 179.1% above its March 23 closing price of $18.63
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments